AFAnthony N. Fabricatore

Anthony N. Fabricatore

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anthony N. Fabricatore has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Continuous glucose monitoring to assess the ecologic validity of dietary glycemic index and glycemic load

    by Anthony N Fabricatore, Cara B Ebbeling, Thomas A Wadden, David S Ludwig

    Background: The circumstances under which the glycemic index (GI) and glycemic load (GL) are derived do not reflect real-world eating behavior. Thus,


  • Targeting dietary fat or glycemic load in the treatment of obesity and type 2 diabetes: A randomized controlled trial

    by A.N. Fabricatore, T.A. Wadden, C.B. Ebbeling, J.G. Thomas, V.A. Stallings, S. Schwartz, D.S. Ludwig


  • Open Access

    Intentional weight loss and changes in symptoms of depression: a systematic review and meta-analysis

    by A N Fabricatore, T A Wadden, A J Higginbotham, L F Faulconbridge, A M Nguyen, S B Heymsfield, M S Faith

    Objective: Obesity is related to increased risk of several health complications, including depression. Many studies have reported improvements in mood with weight loss, but results have been equivocal. The present meta-analysis examined changes in symptoms of depression that were reported in trials of weight loss interventions. Between-groups comparisons of different weight loss methods (for example, lifestyle modification, diet-alone and pharmacotherapy) were examined, as were within-group changes for each treatment type. Method: MEDLINE was searched for articles published between 1950 and January 2009. Several obesity-related terms were intersected with terms related to depression. Results were filtered to return only studies of human subjects, published in English. Of 5971 articles, 394 were randomized controlled trials. Articles were excluded if they did not report mean changes in weight or symptoms of depression, included children or persons with psychiatric disorders (other than depression), or provided insufficient data for analysis. Thirty-one studies (n=7937) were included. Two authors independently extracted a description of each study treatment, sample characteristics, assessment methods and changes in weight and symptoms of depression. Treatments were categorized as lifestyle modification, non-dieting, dietary counseling, diet-alone, exercise-alone, pharmacotherapy, placebo or control interventions. Results: Random effects models found that lifestyle modification was superior to control and non-dieting interventions for reducing symptoms of depression, and marginally better than dietary counseling and exercise-alone programs. Exercise-alone programs were superior to controls. No differences were found for comparisons of pharmacologic agents and placebos. Within-group analyses found significant reductions in symptoms of depression for nearly all active interventions. A meta-regression found no relationship between changes in weight and changes in symptoms of depression in lifestyle modification interventions. Conclusions: On average, obese individuals in weight loss trials experienced reductions in symptoms of depression. Future studies should examine incidence and resolution of clinically significant depressive disorders with weight loss interventions.


  • Constructing common cohorts from trials with overlapping eligibility criteria: implications for comparing effect sizes between trials

    by David L Mount, Patricia Feeney, Anthony N Fabricatore, Mace Coday, Judy Bahnson, Robert Byington, Suzanne Phelan, Sharon Wilmoth, William C Knowler, Irene Hramiak, et al.

    Background Comparing findings from separate trials is necessary to choose among treatment options, however differences among study cohorts may impede these comparisons. Purpose As a case study, to examine the overlap of study cohorts in two large randomized controlled clinical trials that assess interventions to reduce risk of major cardiovascular disease events in adults with type 2 diabetes in order to explore the feasibility of cross-trial comparisons Methods The Action for Health in Diabetes (Look AHEAD) and The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trials enrolled 5145 and 10,251 adults with type 2 diabetes, respectively. Look AHEAD assesses the efficacy of an intensive lifestyle intervention designed to produce weight loss; ACCORD tests pharmacological therapies for control of glycemia, hyperlipidemia, and hypertension. Incidence of major cardiovascular disease events is the primary outcome for both trials. A sample was constructed to include participants from each trial who appeared to meet eligibility criteria and be appropriate candidates for the other trial’s interventions. Demographic characteristics, health status, and outcomes of members and nonmembers of this constructed sample were compared. Results Nearly 80% of Look AHEAD participants were projected to be ineligible for ACCORD; ineligibility was primarily due to better glycemic control or no early history of cardiovascular disease. Approximately 30% of ACCORD participants were projected to be ineligible for Look AHEAD, often for reasons linked to poorer health. The characteristics of participants projected to be jointly eligible for both trials continued to reflect differences between trials according to factors likely linked to retention, adherence, and study outcomes. Limitations Accurate ascertainment of cross-trial eligibility was hampered by differences between protocols. Conclusions Despite several similarities, the Look AHEAD and ACCORD cohorts represent distinct populations. Even within the subsets of participants who appear to be eligible and appropriate candidates for trials of both modes of intervention, differences remained. Direct comparisons of results from separate trials of lifestyle and pharmacologic interventions are compromised by marked differences in enrolled cohorts. Clinical Trials 2009; 6: 416—429. http://ctj.sagepub.com


  • Predictors of attrition and weight loss success: Results from a randomized controlled trial

    by Anthony N. Fabricatore, Thomas A. Wadden, Reneé H. Moore, Meghan L. Butryn, Steven B. Heymsfield, Allison Martin Nguyen


  • Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis

    by A. N. Fabricatore, T. A. Wadden, R. H. Moore, M. L. Butryn, E. A. Gravallese, N. E. Erondu, S. B. Heymsfield, A. M. Nguyen

    Summary: Clinical trials of obesity treatments have been limited by substantial dropout. Participant‐level variables do not reliably predict attrition, and study‐level variables have not yet been examined. We searched MEDLINE and identified 24 large randomized controlled trials of weight loss medications. These trials were comprised of 23 placebo and 32 drug groups. Two authors independently extracted the following for each treatment group: (i) treatment received; (ii) design characteristics (inclusion of a lead‐in period, selection of participants with weight‐related comorbidities, study location and number of study visits); (iii) sample characteristics (sample size, % female, and mean baseline age and body mass index); and (iv) attrition (total, adverse event [AE]‐related and non‐AE‐related) at 1 year. The primary outcome was total attrition, which was significantly related to treatment (i.e. 34.9%, 28.6%, 28.3% and 35.1% in placebo, orlistat, sibutramine and rimonabant groups, respectively, P < 0.0001). In adjusted multivariable models, total attrition was significantly lower in groups that completed a pre‐randomization lead‐in period than in those that did not (29.1% vs. 39.9%, P < 0.01). Gender also was significantly related to total attrition; groups with more women had higher dropout (P < 0.01). The pattern was similar for predicting non‐AE‐related attrition. Findings suggest ways to design studies that maximize retention.


  • Open Access

    Weight Loss Expectations and Goals in a Population Sample of Overweight and Obese US Adults

    by Anthony N. Fabricatore, Thomas A. Wadden, Jeffrey M. Rohay, Janine L. Pillitteri, Saul Shiffman, Andrea M. Harkins, Steven L. Burton

    The purpose of this study was to investigate weight loss expectations and goals in a population sample of US adults who planned to make a weight loss attempt, and to examine predictors of those expectations and goals. Participants were 658 overweight and obese adults (55% women, mean age = 47.9 years, BMI = 31.8 kg/m2) who responded to a telephone survey about weight loss. Respondents reported weight loss expectations (i.e., reductions they realistically expected) and goals (i.e., reductions they ideally desired) for an upcoming “serious and deliberate” weight loss attempt. They also reported the expectations they had, and the reductions they actually achieved, in a previous attempt. Respondents' weight loss expectations for their upcoming attempt (8.0% reduction in initial weight) were significantly more modest than their goals for that attempt (16.8%), and smaller than the losses that they expected (12.0%), and achieved (8.9%) in their most recent past attempt (Ps ≤ 0.003). Women and participants with higher BMIs had greater weight loss expectations and goals. After controlling for BMI, age, and gender, previous weight loss was unrelated to expectations (but was inversely related to goals) for the upcoming weight loss attempt. Results suggest that overweight and obese individuals can select realistic weight loss expectations that are more modest than their ideal goals. BMI and gender appear to be more important than previous weight loss experiences in determining expectations among persons planning a weight loss attempt.


  • Impression management or real change? Reports of depressive symptoms before and after the preoperative psychological evaluation for bariatric surgery

    by Anthony N. Fabricatore, David B. Sarwer, Thomas A. Wadden, Christopher J. Combs, Jennifer L. Krasucki


  • The role of patients' expectations and goals in the behavioral and pharmacological treatment of obesity

    by A N Fabricatore, T A Wadden, L G Womble, D B Sarwer, R I Berkowitz, G D Foster, J R Brock

    Objective: Method: Results: Conclusion: